Saxagliptin: A selective DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

Clinical Medicine Insights: Endocrinology and Diabetes

Volumn 4, Issue , 2011, Pages 1-12

  Shubrook, Jay ^a   Colucci, Randall ^a   Guo, Aili ^a   Schwartz, Frank ^a  

^a OHIO UNIVERSITY   (United States)

Author keywords

DPP 4 inhibitors; Incretin hormones; Saxagliptin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; INCRETIN; METFORMIN; PLACEBO; SAXAGLIPTIN; SULFONYLUREA DERIVATIVE;

ABNORMAL LABORATORY RESULT; ADD ON THERAPY; BACKACHE; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE COURSE; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PREFERENCE; DRUG SAFETY; ECG ABNORMALITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HORMONE ACTION; HUMAN; HYPOGLYCEMIA; LOW DRUG DOSE; MONOTHERAPY; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; QT INTERVAL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 79952729828     PISSN: 11795514     EISSN: 11795514     Source Type: Journal    
DOI: 10.4137/CMED.S5114     Document Type: Review

References (54)

1. World Diabetes Foundation. Available at http://www.worlddiabetes foundation.org/composite-35.htm. Accessed 2009 Jan 31.
2. World Health Organization Media Centre. Available at http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed 2010 Sep 26.
3. National Diabetes Information Clearinghouse. Available at http://diabetes.niddk.nih.gov/dm/pubs/statistics/#allages. Accessed 2009 Jan 31.
4. Huang ES, Basu A, O'Grady M, et al. Projecting the future diabetes population size and related costs for the US. Diabetes Care. 2009;32(12):2225-9.
5. Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the US population in 1988-1994 and 2005-2006. Diabetes Care. 2009;32:287-94.
6. UKPDS UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
7. Holman RR, Paul SK, Bethel MA, et al. Ten year Follow Up of Intensive Glucose Control for Type 2 Diabetes Mellitus. NEJM. 2008;359(15):1577-89.
8. Ohkubo Y, Kishikawa H, Raki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: A randomized prospective 6 year study. Diabetes Res Clin Pract. 1995;28:103.
9. The ADVANCE Collaborative Group. Intensive Blood Glucose Control and VascularOutcomes in Patients with Type 2 Diabetes. NEJM. 2008;358: 2560-72.
10. Duckworth W, Abraira C, Moritz T, et al. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. NEJM. 2009;1:1-11.
11. Grant R, Buse JB, Meigs JB, et al. Quality of Diabetes Care in US. Academic Medical Centers: Low rates of medical regimen change. Diabetes Care. 2005;28(2):337-42.
12. Shah, BR, Hux JE, Laupacis A. Clinical Inertia in Response to Inadequate Glycemic Control: Do specialists differ from primary care physicians? Diabetes Care. 2005;28:600-6.
13. Green B, Flatt P, Bailey C. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diabetes and vascular disease research. 2006;(3):159-65.
14. Sebokova E, Christ A, Boehringer M, et al. Dipeptidyl peptidase IV inhibitors: The next generation of new promising therapies for the management of type 2 diabetes. Current Topics in Medicinal Chemistry. 2006;7: 547-55.
15. Ahn JH, Shin MS, Jun Ma, et al. Synthesis, biological evaluation and structural determination of β-aminoacyl-containing cyclic hydrazine derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors. Bioorganic and Medicinal Chemistry Letters. 2007;17:2622-8.
16. Kuhn Bernd, Hennig, Michael, Mattei. Patrizio (March 2007), Molecular Recognition of Ligands in Dipeptidyl Peptidase IV. Current Topics in Medicinal Chemistry. 7:609-19.
17. AACE Diabetes Mellitus Clinical Practice Guideline Task Force. American Association of Clinical Endocrinologists Medical Guidelines for Management of Diabetes Mellitus. Available at www.aace.com/pub. Accessed 9-30- 2010.
18. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group UK Prospective Diabetes Study (UKPDS) Group. Diabetes. 1995;44:1249-58.
19. Peters JU. 11 years of Cyanopyrrolidines as DPP-IV Inhibitors. Current topics in Medicinal Chemistry. 2007;7:579-95.
20. Veken PV, Haemers A, Augustyns K. Prolyl peptidase related to dipeptidyl peptidase IV: Potential of specific inhibitors in drug discovery. Current Topics in Medicinal Chemistry. 2007;7:621-35.
21. Ferraris D, Belyakov S, Li W, et al. "Azetidine-Based Inhibitors of Dipeptidyl Peptidase IV (DPP IV)". Current Topics in Medicinal Chemistry. 2007;7:597-608.
22. ® (saxagliptin) package insert. 2009 Jul. Bristol-Myers Squibb.
23. Kirby MS, Dorso C, Wang A, et al. In Vitro enzymologic characteristics of saxagliptin, a highly potent and selective DPP-4 inhibitor with slow binding characteristics. Abstract presented at: 3rd International Conference on Dipeptidyl Peptidase and Related Proteins. Antwerp Blegium. 2008;23-5.
24. Kirby M, Yu D, O'Conner S, et al. Inhibitor Selectivity in clinical application of DPP-4 inhibition. Clin Sci. 2010;118(1):31-41.
25. Boulton D, Geraldes M. Safety, tolerability, pharamcokinetics and pharmacodynamics of once daily oral doses of saxagliptin for 2 weeks in type 2 diabetic and healthy subjects. Diabetes. 2009;56 Suppl 1:606P.
26. Holst JJ. Glucagon -like peptide 1(GLP-1): an intestinal hormone signaling nutritional abundance, with unusual therapeutic potential. Trends Endocrinol Metab. 1999;10:229-35.
27. Mest HJ, Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia. 2005;48:616-20.
28. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes. Systematic review and meta-analysis. JAMA. 2007;298(2): 194-206.
29. Boulton DW, Geraldes M. Safety, tolerability, pharmacokinetics of a oncedaily oral doses of saxagliptin for 2 weeks in type 2 diabetic and healthy subjects. 2007. Presented as poster (0606-P) at the American Diabetic Association's 67th annual scientific session.
30. COCHRANE database: Available at http://mrw.interscience.wiley.com/cochrane_clcentral_articles_fs.html. Accessed 2009 Jan 31.
31. Clinical trials.gov. Available at http://clinicaltrials.gov/ct2/results?term=saxagliptin. Accessed on 2009 Jan 31.
32. Bristol-Myers Squibb. Study of BMS-477118 as monotherapy in titration in subjects with type 2 diabetes who are not controlled with diet and exercise. Available at http://www/clinicaltrials.gov/ct2/show/study/NCT00316082.
33. Rosenstock J, Sankoh SL, L JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug -naïve patients with type 2 diabetes. Diabetes Obes Metab. 2008;10:376-86.
34. Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin monotherapy in treatment naïve patients with type 2 diabetes. Curr Med Res Opin. 2009. epub.
35. DeFronzo RA, Hissa M, Garber AJ, et al. The Efficacy and Safety of Saxagliptin when added to metformin therapy in patients inadequately controlled type 2 diabetes on metformin alone. Diabetes Care. 2009;32(9):1649-55.
36. DeFronzo R, Hissa MN, Garber AJ, et al. Once daily saxaglipitin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with type 2 Diabetes Mellitus. Abstract presented at the 69th Scientific Sessions of the American Diabetes Association. 2009.
37. Jadinsky M, Pfutzner A, Paz-Pacheco E, et al. for CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type diabetes compared with either monotherapy: a randomized controlled trial. Diab Obes Metab. 2009;11(6): 611-22.
38. Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes:a randomized control trial. Int J clin Pract. 2009;63(9):1395-406.
39. Bristol-Myers Squibb. A Multicenter, randomized, double blind, placebo controlled phase 3 trial to evaluate the efficacy and safety of saxagliptin in combination with gylburide in subjects with type 2 diabetes who have inadequate glycemic control on glyburide alone. Available at http://www.clinicalstudyresults.org/documents/company-study_9577_7.pdf
40. Allen E, Hollander P, Li J, Chen R. Saxagliptin added to a thiazolidinedione improves glycemic control in inadequately controlled type 2 diabetes. 2008. Presented as an abstract (#859) at the 68th American Diabetes Association's annual scientific session.
41. Patel CG, Wolf RA, Komoroski B, et al. No meaningful pharmacokinetic drug-drug interactions between saxagliptin and pioglitazone in healthy subjects. Presented at the American College of Clinical Pharmacy (ACCP) Annual Meeting 2007. Abstract 226.
42. Patel CG, Li L, Komoroski B, et al. No meaningful pharmacokinetic drug-drug interactions between saxagliptin and glyburide in healthy subjects. Presented at the American College of Clinical Pharmacy (ACCP) Annual Meeting 2007. Abstract 212.
43. Patel CG, Komoroski B, Brenner E, et al. No meaningful pharmacokinetic drug-drug interactions between saxagliptin and metformin in healthy subjects. Presented at the American College of Clinical Pharmacy (ACCP) Annual Meeting 2007. Abstract 213.
44. Patel C, Castaneda L, Frevert U, et al. Single dose pharmacokinetics and safety of saxagliptin in subjects with hepatic impairment compared with healthy subjects. Abstract presented at 68th Scientific Sessions of the American Diabetes Association 2008. Abstract 537-P.
45. Chen R, Dononvan M, Rusnak JM. Saxagliptin used as monotherapy or in combination with other antihyperglycemic agents does not significantly increase risk of hypoglycemia. Diabetes. 2009;58 Suppl 1:2082P.
46. US Dept HHS FDA. Guidance for Industry diabetes mellitus evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. December 2008 Available at http://www.fda.gov/download/Drugs/GuidelinesCompliance-RegulatoryInformation/Guidances/ucm071627.pdf
47. Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgraduate Medicine. 2010;122(3):16-27.
48. AstraZeneca:Bristol-Myers Squibb. Does saxagliptin reduce the risk of cardiovascular
49. outcomes when used alone or added to other diabetes medications (SAVOR-TIMI 53. Available at http://www.clinicaltrials.gov/ct2/show/NCT01107886.
50. Pratley RE. The New Science of GLP-1: Effects Beyond Glucose Control. Johns Hopkins Advanced Studies in Medicine. 2008;8(11):393-9.
51. Wani J, John-Kalarickal J, Fonseca V. Dipeptidal Peptidase- 4 as a New Target of Action for Type 2 Diabetes Mellitus: A Systematic Review. Cardiology Clinics. 2008;26:639-48.
52. Gallwitz B. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data. Int J Clin Pract. 2006;60:1654-61.
53. Brubaker PL, Drucker DJ. Mini Review: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology. 2004;145:2653-9.
54. Kulasa K, Edelman S. Saxagliptin: The evidence for its place in the treatment of type 2 diabetes mellitus. Core Evidence. 2010;5:23-37.